Dave Muoio

Published yesterday in PLoS ONE, the data suggests an alternative to the six-minute walk test often conducted in clinics to measure functional capacity.

The deal is valued at about $194 million and will drive about a third of the telemedicine company's expected revenue moving forward.

Providers will be able to have in-app live video conversations with chronic pain and movement disorder patients, as well as prescribe new settings for their neuromodulation therapies from afar.

Set to close in Q2, the deal will provide the payer's healthcare services subsidiary with an integrated virtual care offering.

Industry regulatory leaders outline the best approaches for digital health companies looking to make sense of FDA's long-in-the-tooth enforcement discretion guidelines.

Saykara's founder and team will be augmenting Nuance's R&D division.

Thirty mobile health apps from larger healthcare information technology companies were susceptible to a broken object level authorization (BOLA) attack.

The company hopes that its more descriptive reports will distinguish the personal ECG offering from others limited to atrial fibrillation detection alone.

The tech company elaborated on its established digital health and wellness vision while improvising with the demands of an unexpected pandemic.

Lucira's molecular testing kit allows individuals to collect their own nasal sample and insert it into a device that provides results in under 30 minutes. The company is aiming to sell the single-use tests for roughly $50.